Rachel M Koldej

13PUBLICATIONS
79CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsHaematological tumoursAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 19, 2026
A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years.

|Oct 16, 2026
Prospective phase I study of nivolumab to promote graft-versus-tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation.

|Dec 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Sasanka M Handunnetti, Amit Khot, Piers Blombery

|Jan 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

Allison Barraclough, Sze Ting Lee, Melinda Burgess

|Oct 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.

Meng-Xiao Luo, Tania Tan, Marie Trussart

|Apr 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.

Sasanka M Handunnetti, Mary Ann Anderson, Kate Burbury

Pageof 3

Frequent Collaborators

7 joint publications

David S Ritchie

3 joint publications

Ashvind Prabahran

3 joint publications

Stephen Lade

3 joint publications

John F Seymour